Is Neuland Laboratories the Best Stock in Its Sector? A Look at the Numbers

Is Neuland Laboratories the best stock in its sector? The stock trades on the NSE at Rs 21,500 as of 05 October 2026, within its 52-week range of Rs 11,500.00 to Rs 24,225.00. Neuland Laboratories Ltd manufactures active pharmaceutical ingredients and provides custom manufacturing services to pharmaceutical companies.

Neuland Laboratories sits in the Healthcare sector, and its 19.42% ROE and 55.41x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Neuland Laboratories

Neuland Laboratories Ltd manufactures active pharmaceutical ingredients and provides custom manufacturing services to pharmaceutical companies. The stock is trading about 11 percent below its 52-week high after nearly doubling from its 52-week low, and it trades at a very high absolute share price. At a market capitalisation of Rs 27,580 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Neuland Laboratories the Best Stock in Its Sector?

Neuland Laboratories makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 19.42% ROE with a 55.41x P/E against the sector's 37.53x Industry P/E. Neuland Laboratories' 55.41x P/E is above the 37.53x Industry P/E, a premium built on a strong 19.42% ROE, though a 14.72x price to book leaves little room for disappointment.

Metric	Neuland Laboratories
CMP (NSE)	Rs 21,500.00
52-Week High / Low	Rs 24,225.00 / Rs 11,500.00
Market Cap	Rs 27,580 Cr
P/E (TTM) vs Industry P/E	55.41x vs 37.53x
P/B	14.72
ROE	19.42%
EPS (TTM)	Rs 387.98
Dividend Yield	0.16%
Debt to Equity	0.16

Compare Neuland Laboratories Against Other Healthcare Sector Stocks

How Neuland Laboratories Compares Against Its Healthcare Sector Peers

The table below sets Neuland Laboratories against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Neuland Laboratories	27,580	55.41	19.42%	0.16
Innova Captab	7,275	47.23	12.92%	0.32
Jagsonpal Pharmaceuticals	1,586	34.89	15.60%	0.03
Peer average (2 companies)	-	41.06	14.26%	0.17

Against this peer set, Neuland Laboratories's 19.42% ROE is above the 14.26% peer average, and its P/E of 55.41x runs above the peer average of 41.06x. Neuland Laboratories' 55.41x P/E is above the 37.53x Industry P/E, a premium built on a strong 19.42% ROE, though a 14.72x price to book leaves little room for disappointment.

What Makes Neuland Laboratories Worth Watching in Healthcare

• Strong ROE: A 19.42% ROE is well above most Healthcare peers covered in this series.
• Low leverage: A debt to equity ratio of 0.16 is comfortable for an API manufacturer.
• Rich valuation: A 55.41x P/E against a 37.53x Industry P/E, alongside a 14.72x price to book, is demanding.

Neuland Laboratories Valuation: Is It Justified?

Neuland Laboratories' 55.41x P/E is above the 37.53x Industry P/E, a premium built on a strong 19.42% ROE, though a 14.72x price to book leaves little room for disappointment. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Nelcast the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Neuland Laboratories and other Healthcare sector stocks.

How to Track Neuland Laboratories Before You Invest

Before deciding whether Neuland Laboratories deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Neuland Laboratories to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Neuland Laboratories earns a place in the best stock in its sector conversation on the strength of a 19.42% ROE and a P/E of 55.41x against a 37.53x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Neuland Laboratories the best stock in its sector?

Ans. Neuland Laboratories has a 19.42% ROE and trades at 55.41x P/E against a 37.53x Industry P/E, and compares above the peer average ROE of 14.26% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Neuland Laboratories?

Ans. Neuland Laboratories was trading at Rs 21,500.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 11,500.00 to Rs 24,225.00.

What sector does Neuland Laboratories belong to?

Ans. Neuland Laboratories is classified under the Healthcare sector on Univest.

How does Neuland Laboratories compare to its sector peers on P/E?

Ans. Neuland Laboratories's P/E of 55.41x is above the 41.06x average of the 2 named peers compared in this article.

What is Neuland Laboratories's return on equity?

Ans. Neuland Laboratories reported a return on equity of 19.42%, which is above the 14.26% average of its named peers in this comparison.

Should I invest in Neuland Laboratories based on its sector position?

Ans. Neuland Laboratories's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Neuland Laboratories the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories has a 19.42% ROE and trades at 55.41x P/E against a 37.53x Industry P/E, and compares above the peer average ROE of 14.26% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Neuland Laboratories?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories was trading at Rs 21,500.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 11,500.00 to Rs 24,225.00."}}, {"@type": "Question", "name": "What sector does Neuland Laboratories belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Neuland Laboratories compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories's P/E of 55.41x is above the 41.06x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Neuland Laboratories's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories reported a return on equity of 19.42%, which is above the 14.26% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Neuland Laboratories based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Neuland Laboratories's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}